Probiotics may shield cancer patients from Immunotherapy's gut woes
NCT ID NCT06508034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors who are starting or have recently started immunotherapy. The goal is to see if a simple probiotic can reduce this risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden immune clues in tumors?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- A virtual pharmacy visit may ease opioid fears for cancer patients
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
- A smartphone app may help young cancer survivors get fitter — a trial puts it to the test